← Back to Neuphoria Therapeutics Stock
Neuphoria Therapeutics (NEUP) News
ADELAIDE, Australia and CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the initiation of patient screening for the Phase 3 AFFIRM-1 trial evaluating the safety and efficacy of BNC210 for the acute, as-needed treatment of social anxiety disorder (SAD).
Bionomics (BNOX) has released an update. Bionomics Limited, an Australian biotech firm, has entered into a Securities Purchase Agreement with selec…
ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced it has entered into a securities purchase agreement with an institutional accredited investor to purchase American Depository Shares (“ADS”) (or pre-funded warrants in lieu thereof) and accompanying warrants in a three-tranche private placement.
ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced it has entered into a securities purchase agreement with an institutional accredited investor to purchase American Depository Shares (“ADS”) (or pre-funded warrants in lieu thereof) and accompanying warrants in a three-tranche private placement.
ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that Spyridon “Spyros” Papapetropoulos, M.D., PhD, President and Chief Executive Officer of Bionomics will be giving an oral presentation and presenting two posters about BNC210 as a potential treatment for social anxiety disorder and post-traumatic stress disorder (PTSD) at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place May 28 – 31 in Miami Beach, Florida. Details of the presentations are as follows:
Thursday, Bionomics Limited (NASDAQ: BNOX ) released a full dataset analysis from its Phase 2b ATTUNE trial of BNC210 in patients with post- traumatic stress disorder (PTSD) . In September 2023, Bionomics reported the topline results for the Phase 2b ATTUNE trial of BNC210 for PTSD, demonstrating that the trial met its primary endpoint and several secondary endpoints and that BNC210 was generally well tolerated . The primary endpoint of mean change from baseline in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity score was met, showing that BNC210 led to a statistically significant improvement vs placebo (p<0.05) at Week 12 with an effect size of 0.40. The improvement in CAPS-5 … Full story available on Benzinga.com
Bionomics (Nasdaq: BNOX) announced positive Phase 2b trial results for BNC210 in treating post-traumatic stress disorder (PTSD), showing statistically significant improvements with a favorable safety profile. BNC210 demonstrated rapid onset of clinical efficacy and sustained effects, meeting primary and secondary endpoints. The trial data supports BNC210 as a potential highly differentiated treatment with a novel mechanism of action, positioning it as a promising therapy for PTSD patients.
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications.
ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY.
Small-cap stocks are particularly vulnerable to higher interest rates. So it's not surprising that many of these stocks are struggling in a higher-for-longer rate environment.